Edition:
India

Essex Bio-Technology Ltd (1061.HK)

1061.HK on Hong Kong Stock

6.60HKD
18 Apr 2019
Change (% chg)

HK$-0.22 (-3.23%)
Prev Close
HK$6.82
Open
HK$6.78
Day's High
HK$6.78
Day's Low
HK$6.50
Volume
371,000
Avg. Vol
373,674
52-wk High
HK$8.63
52-wk Low
HK$3.79

Latest Key Developments (Source: Significant Developments)

Essex Bio-Technology Says Acquisition Of Land Use Rights And Construction Of Production Plant
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Essex Bio-Technology Ltd <1061.HK>::SAYS ACQUISITION OF LAND USE RIGHTS AND CONSTRUCTION OF PRODUCTION PLANT IN ZHUHAI FOR RMB9.6 MILLION.ESTIMATED CONSTRUCTION COSTS FOR CONSTRUCTION OF PRODUCTION PLANT WILL BE RMB227.6 MILLION.  Full Article

Essex Bio-Technology Posts FY Profit Of HK$167.3 Mln
Thursday, 15 Mar 2018 

March 15 (Reuters) - Essex Bio-Technology Ltd <1061.HK>::‍FY TURNOVER HK$899.6 MILLION VERSUS HK$775.7 MILLION.‍PROFIT FOR YEAR HK$167.3 MILLION VERSUS HK$136.3 MILLION​.‍DIRECTORS PROPOSE A FINAL DIVIDEND OF HK$0.025 PER ORDINARY SHARE​.  Full Article

Essex bio-technology terminates proposed KDR programme​
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Essex Bio-technology Ltd <1061.HK>::Terminated proposed KDR programme​.‍KDR programme termination to not have adverse effect on co's financial position​.  Full Article

Essex Bio-Technology posts HY profit attributable of HK$77.1 mln
Friday, 11 Aug 2017 

Aug 11 (Reuters) - Essex Bio-technology Ltd <1061.HK>:HY profit attributable HK$77.1 million versus HK$62 million.HY turnover HK$437.6 million versus HK$363.9 million.Has resolved on 11 August 2017 to declare an interim dividend of HK$0.025 per share for six months ended 30 June 2017.  Full Article

Essex Bio-Technology announces approval to commercialise Tobramycin eye drops in China
Tuesday, 13 Jun 2017 

June 13 (Reuters) - Essex Bio-technology Ltd <1061.HK> ::Announces approval to commercialise preservative-free single-dose Tobramycin eye drops in China.Approved product is expected to be launched in market at or around end of 2017.  Full Article